.jpg)
1 hour ago
3
Article content
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
BOSTON — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic dystrophy type 1 (DM1).
Article content
Article content
Article content
Ahead of IDMC-15, PepGen’s President and Chief Executive Officer, James McArthur, PhD, will present single and initial multiple ascending dose data for PGN-EDODM1 at the 6th Annual Pharma Day, co-hosted by Euro-DyMA and the Myotonic Dystrophy Foundation (MDF), on May 26, 2026, at 11:00–11:20am EDT in Saguenay, Quebec, Canada.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
IDMC-15 Presentation Details:
Article content
T
Article content
itle:
Article content
Analysis of Individual Patient Mis-Splicing Data from PGN-EDODM1, an Investigational Therapy for Myotonic Dystrophy Type 1 (DM1)
Article content
Article content
Presentation Type:
Article content
Late-Breaking Oral Presentation
Article content
Article content
Session:
Article content
Late-Breaking Industry Session
Article content
Article content
Date & Time:
Article content
Thursday, May 28
Article content
th
Article content
at 3:15–4:15pm EDT
Article content
Article content
Presenter:
Article content
James McArthur, PhD, President and Chief Executive Officer of PepGen
Article content
Title:
Article content
The FREEDOM-DM1 clinical trial demonstrated strong splicing correction with single doses of PGN-EDODM1, with an acceptable safety profile
Article content
Article content
Presentation Type:
Article content
Poster Session
Article content
Article content
Date & Time:
Article content
Wednesday, May 27
Article content
th
Article content
at 10:45am–12:15pm EDT and Thursday, May 28
Article content
th
Article content
at 4:15–7:00pm EDT
Article content
Article content
Presenter:
Article content
Dr. Johanna Hamel, Associate Professor of Neurology, Pathology and Laboratory Medicine at the University of Rochester Medical Center
Article content
Following the conference, the presentations presented at IDMC-15 will be available on PepGen’s website under Scientific Publications.
Article content
About PGN-EDODM1
Article content
PGN-EDODM1, PepGen’s investigational candidate in development for the treatment of DM1, utilizes the Company’s proprietary EDO technology to deliver a therapeutic oligonucleotide that is designed to restore the normal splicing function of MBNL1, a key RNA splicing protein. PGN-EDODM1 addresses the deleterious effects of cytosine-uracil-guanine (CUG) repeat expansion in the dystrophia myotonica protein kinase (DMPK) transcripts which sequester MBNL1, by binding to the pathogenic CUG trinucleotide repeat expansion present in the DMPK transcripts and disrupting the binding between the CUG repeat expansion and MBNL1. PepGen believes this innovative therapeutic approach may have considerable advantages over oligonucleotide modalities that rely on knockdown or degradation of the DMPK transcripts as it will allow the DMPK transcripts to continue to perform their normal function within the cell, while also liberating MBNL1 to correct downstream mis-splicing events. The U.S. Food and Drug Administration has granted PGN-EDODM1 both Orphan Drug and Fast Track Designations for the treatment of patients with DM1. The European Medicines Agency (EMA) has granted Orphan Designation for PGN-EDODM1.
Article content
Article content
About Myotonic Dystrophy Type 1 (DM1)
Article content
Myotonic dystrophy type 1 (DM1) is a rare, progressive, and highly variable genetic neuromuscular disease caused by an abnormal expansion of cytosine-thymine-guanine (CTG) repeats in the dystrophia myotonica protein kinase (DMPK) gene. DM1 affects over 115,000 individuals in the U.S. and EU and is characterized by widespread, multisystem symptoms that may include myotonia, progressive muscle weakness, fatigue, cardiac abnormalities, respiratory impairment, and cognitive dysfunction. The disease is driven by toxic RNA transcripts containing expanded cytosine-uracil-guanine (CUG) repeats that sequester muscle blind-like 1 (MBNL1), a key RNA splicing protein, leading to widespread mis-splicing across multiple tissues. There are currently no approved disease-modifying therapies for DM1, underscoring the significant unmet medical need for patients living with the disease.
Article content
About PepGen
Article content
PepGen Inc. is a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
Article content
For more information, please visit PepGen.com. Follow PepGen on LinkedIn and X.
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
Investor Contact
Article content
Article content
Laurence Watts
Article content
Article content
New Street Investor Relations
Article content
Article content
Article content
Media Contact
Article content
Article content
Julia Deutsch
Article content
Article content
Lyra Strategic Advisory
Article content
Article content
Article content
English (US)